Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer

被引:9
|
作者
Sharma Saha, Sweta [1 ]
Gentles, Lucy [1 ]
Bradbury, Alice [1 ]
Brecht, Dominik [2 ]
Robinson, Rebecca [3 ]
O'Donnell, Rachel [1 ,4 ]
Curtin, Nicola J. [1 ]
Drew, Yvette [1 ,5 ]
机构
[1] Newcastle Univ, Fac Med Sci, Translat & Clin Res Inst, Ctr Canc, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Univ Konstanz, Dept Chem Biol, D-78464 Constance, Germany
[3] Newcastle Univ, Dept Biomed Nutrit & Sports Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Newcastle Hosp NHS Fdn Trust, Northern Ctr Gynaecol Surg, Northern Canc Alliance, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England
[5] Newcastle Hosp NHS Fdn Trust, Northern Ctr Canc Care NCCC, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England
关键词
DNA damage repair; chemotherapy; ovarian cancer; biomarker; STRAND BREAK REPAIR; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; OPEN-LABEL; PLATINUM; CARCINOMA; INHIBITOR; SURVIVAL; MULTICENTER; SENSITIVITY;
D O I
10.3390/cancers13061420
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Several chemotherapy drugs are approved for ovarian cancer treatment in the neo-adjuvant/adjuvant setting as well as following relapse. These include carboplatin, paclitaxel, doxorubicin, topotecan, PARP inhibitors (PARPi), and gemcitabine. However, except for PAPRi, there are no predictive biomarkers to guide the choice of drug. The majority of chemotherapeutic drugs function by inducing DNA damage or inhibiting its repair. However, the association of DNA damage repair (DDR) pathway alterations with therapy response remain unclear. In this study, using a panel of 14 ovarian cancer cell lines, 10 patient ascites-derived primary cultures and bioinformatic analysis of The Cancer Genome Atlas (TCGA) ovarian cancer dataset, we identified the role of genomic/transcriptomic and/or functional alterations in DDR pathways as determinants of therapy response. Defective DNA damage response (DDR) pathways are enabling characteristics of cancers that not only can be exploited to specifically target cancer cells but also can predict chemotherapy response. Defective Homologous Recombination Repair (HRR) function, e.g., due to BRCA1/2 loss, is a determinant of response to platinum agents and PARP inhibitors in ovarian cancers. Most chemotherapies function by either inducing DNA damage or impacting on its repair but are generally used in the clinic unselectively. The significance of HRR and other DDR pathways in determining response to several other chemotherapy drugs is not well understood. In this study, the genomic, transcriptomic and functional analysis of DDR pathways in a panel of 14 ovarian cancer cell lines identified that defects in DDR pathways could determine response to several chemotherapy drugs. Carboplatin, rucaparib, and topotecan sensitivity were associated with functional loss of HRR (validated in 10 patient-derived primary cultures) and mismatch repair. Two DDR gene expression clusters correlating with treatment response were identified, with PARP10 identified as a novel marker of platinum response, which was confirmed in The Cancer Genome Atlas (TCGA) ovarian cancer cohort. Reduced non-homologous end-joining function correlated with increased sensitivity to doxorubicin, while cells with high intrinsic oxidative stress showed sensitivity to gemcitabine. In this era of personalised medicine, molecular/functional characterisation of DDR pathways could guide chemotherapy choices in the clinic allowing specific targeting of ovarian cancers.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 50 条
  • [1] Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting
    Bradbury, Alice
    O'Donnell, Rachel
    Drew, Yvette
    Curtin, Nicola J.
    Saha, Sweta Sharma
    CANCERS, 2020, 12 (07) : 1 - 17
  • [2] The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
    Arai, Hiroyuki
    Elliott, Andrew
    Xiu, Joanne
    Wang, Jingyuan
    Battaglin, Francesca
    Kawanishi, Natsuko
    Soni, Shivani
    Zhang, Wu
    Millstein, Joshua
    Sohal, Davendra
    Goldberg, Richard M.
    Hall, Michael J.
    Scott, Aaron J.
    Khushman, Moh'd
    Hwang, Jimmy J.
    Lou, Emil
    Weinberg, Benjamin A.
    Marshall, John L.
    Lockhart, Albert C.
    Stafford, Phillip
    Zhang, Jian
    Moretto, Roberto
    Cremolini, Chiara
    Korn, W. Michael
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3234 - 3242
  • [3] Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
    Stefanou, Dimitra T.
    Bamias, Aristotelis
    Episkopou, Hara
    Kyrtopoulos, Soterios A.
    Likka, Maria
    Kalampokas, Theodore
    Photiou, Stylianos
    Gavalas, Nikos
    Sfikakis, Petros P.
    Dimopoulos, Meletios A.
    Souliotis, Vassilis L.
    PLOS ONE, 2015, 10 (02):
  • [4] The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer
    Al-Rawi, Duaa H.
    Rusk, Nicole
    Friedman, Claire F.
    CLINICAL CANCER RESEARCH, 2023, 29 (09) : 1645 - 1647
  • [5] Novel biomarkers for DNA damage response pathways: Insights and applications for cancer therapy
    O'Connor, Mark
    PROTEOMICS, 2006, : 69 - 71
  • [6] Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer
    Yin, Ming
    Grivas, Petros
    Wang, Qi-En
    Mortazavi, Amir
    Emamekhoo, Hamid
    Holder, Sheldon L.
    Drabick, Joseph J.
    Woo, Michele Sue-Ann
    Pal, Sumanta
    Vasekar, Monali
    Folefac, Edmund
    Clinton, Steven K.
    Monk, Paul
    Joshi, Monika
    ONCOLOGIST, 2020, 25 (08): : 680 - 688
  • [7] Targeting DNA damage response pathways in cancer
    Florian J. Groelly
    Matthew Fawkes
    Rebecca A. Dagg
    Andrew N. Blackford
    Madalena Tarsounas
    Nature Reviews Cancer, 2023, 23 : 78 - 94
  • [8] Targeting DNA damage response pathways in cancer
    Groelly, Florian J.
    Fawkes, Matthew
    Dagg, Rebecca A.
    Blackford, Andrew N.
    Tarsounas, Madalena
    NATURE REVIEWS CANCER, 2023, 23 (02) : 78 - 94
  • [9] DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
    Ovejero-Sanchez, Maria
    Gonzalez-Sarmiento, Rogelio
    Herrero, Ana Belen
    CANCERS, 2023, 15 (02)
  • [10] Functional interplay between the DNA damage response and ARF pathways in human cancer
    Gorgoulis, V. G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S16 - S16